Nucleic Acid News and Research

RSS

Ribosomes spontaneously change their form during protein production

Ribosomes, the construction sites for proteins, are far more complex than previously assumed. During the production of proteins they constantly and spontaneously change their form. This performance of eukaryotic ribosomes has now been demonstrated for the first time by scientists at Charité - Universitätsmedizin Berlin, the Max-Planck-Institut für Molekulare Genetik in Berlin, and Cornell University in New York, with the aid of special electron microscopic and biophysical methods.

24 Nov 2011

New data from Santaris Pharma miravirsen Phase 2a trial on HCV

Santaris Pharma A/S, a clinical-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies, presents new data from the Phase 2a trial showing that miravirsen given as a four-week monotherapy treatment provided robust dose-dependent anti-viral activity with a mean reduction of 2 to 3 logs from baseline in HCV RNA (log10 IU/mL) that was maintained for more than four weeks beyond the end of therapy.

6 Nov 2011

Gen-Probe receives FDA approval for APTIMA HPV assay

Gen-Probe Incorporated announced today that the US Food and Drug Administration (FDA) has approved its APTIMA HPV assay, an amplified nucleic acid test that detects high-risk strains of human papillomavirus (HPV) that are associated with cervical cancer and precancerous lesions.

31 Oct 2011

Intracellular nucleic acid sensors can trigger autoimmune disease

Bruce Beutler, MD, a co-recipient of the 2011 Nobel Prize in Medicine, has coauthored an article describing a novel molecular mechanism that can cause the body to attack itself and trigger an autoimmune disease.

28 Oct 2011

Mirna, Silence enter agreement to assess delivery systems for novel microRNAs

Silence Therapeutics plc, a leading RNA interference (RNAi) therapeutics company, today announced that it has entered into an agreement with Mirna Therapeutics Inc., a biopharmaceutical company pioneering microRNA-based therapeutics for cancer, to assess the delivery capabilities of Silence's proprietary AtuPLEX and DBTC delivery systems for Mirna's novel microRNAs.

24 Oct 2011

Sewage provides perfect ecosystem for studying diversity of uncharacterized viral populations

Raw sewage provides a perfect ecosystem for studying the diversity of viral populations that remain uncharacterized. This is one of the principal conclusions of a study published in the journal mBio by a team comprising experts from the UB's Laboratory of Water and Food Viral Pollution, Washington University and the University of Pittsburgh, under the direction of James Pipas.

22 Oct 2011

DFG announces establishment of twelve research units

The Deutsche Forschungsgemeinschaft has established nine new Research Units and three Clinical Research Units. The decision was made by the Joint Committee of Germany's central research funding organisation at its October meeting in Bonn.

22 Oct 2011

SomaLogic, Novartis enter multi-year research agreement

SomaLogic, Inc., announced today that it has entered into a multi-year research agreement with Novartis to use its unique proprietary proteomics technology to accelerate Novartis' drug discovery and development efforts.

19 Oct 2011

FDA clears BioHelix IsoAmp HSV molecular diagnostic assay

BioHelix Corporation has received U.S. Food and Drug Administration (FDA) 510(k) clearance for the company's first molecular diagnostic assay, the IsoAmp HSV Assay. The diagnostic test is intended for the detection of Herpes Simplex Virus (HSV1 & HSV2) in genital and oral lesion specimens from symptomatic patients.

18 Oct 2011

Researchers identify set of proteins that affect development of varicose veins

A new discovery published in the October 2011 print issue of The FASEB Journal explains for the first time what kicks off the process that causes varicose veins.

30 Sep 2011

Polyplus-transfection appoints ten additional biologists and chemists to support multiple pre-clinical studies

Polyplus-transfection SA, which specializes in the development of innovative solutions for the delivery of nucleic acids in research and therapeutics, today celebrates ten years of continuous growth.

15 Sep 2011

InteRNA, Silence partner to develop novel microRNA therapeutics for cancer

Silence Therapeutics plc, a leading global RNA interference (RNAi) therapeutics company, and InteRNA Technologies B.V., a biopharmaceutical company developing pathway targeted microRNA-based therapeutics for cancer, today announce that they have entered into an agreement to develop novel microRNA therapeutics for the treatment of cancer.

12 Sep 2011

Low-cost, portable technique can detect specific proteins in human blood

Blood tests are important diagnostic tools. They accurately tease-out vanishingly small concentrations of proteins and other molecules that help give a picture of overall health or signal the presence of specific diseases. Current testing procedures, however, are expensive and time-consuming, while sophisticated test equipment is bulky and difficult to transport.

2 Sep 2011

Southampton scientists to develop new single molecule DNA sequencing method

A new method of single molecule DNA sequencing is being developed by scientists at the University of Southampton with funding from the Biotechnology and Biological Sciences Research Council's Strategic Tools and Resources Development Fund.

26 Aug 2011

FDA clears IQuum's Liat influenza A/B assay, analyzer

IQuum, Inc. announced today that it has received U.S. Food and Drug Administration (FDA) 510(k) clearance to market the Liat Influenza A/B Assay and the Liat Analyzer.

23 Aug 2011

Study reveals structure of ribosomal assembly intermediate

As part of a joint research effort with the University of Michigan, scientists from the Florida campus of The Scripps Research Institute have for the first time defined the structure of one of the cell's most basic engines, which is required for cell growth, as it assembles from its components.

17 Aug 2011

TrovaGene regains ownership of worldwide rights to transrenal technology

TrovaGene, Inc., a developer of transrenal molecular diagnostics, confirmed today that it regained ownership of its worldwide rights and control over its patent estate for transrenal technology for non-invasive prenatal applications and cancer through the termination of a license agreement between TrovaGene and Sequenom, Inc.

10 Aug 2011

Akonni to develop closed amplicon RT-PCR microarray for virus detection in CSF

Akonni Biosystems, a molecular diagnostics company that develops novel nucleic acid extraction and microarray-based testing systems designed to rapidly and economically analyze biological samples, today announced receipt of a $300K grant from the National Institutes of Health.

5 Aug 2011

IntegenX's RapidHIT Human Identification Systems now include Promega's STR amplification reagents

IntegenX Inc. and Promega Corporation today announced that commercial deliveries of RapidHIT™ 200 Human Identification Systems will include Promega's nucleic acid purification and short tandem repeat (STR) amplification reagents.

4 Aug 2011